# Ono Venture Investment

Ono Venture Investment is a Venture Capital based in South San Francisco, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** South San Francisco, United States
- **Region:** North America
- **Address:** 601 Gateway Blvd Suite 1010, South San Francisco, CA 94080, USA
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** www.onoventure.com
- **LinkedIn:** https://www.linkedin.com/company/ono-venture-investment

## Regulatory record

- **Reports private funds:** No

## About

The Official Website of Ono Venture Investment, Inc. For access to innovative technologies/novel therapeutic drug targets and collaboratio with early stage startup companies, OVI makes a strategic investment in such startup companies with cutting-edge technologies.

## Sectors

- Oncology
- Immunology & Inflammation
- Neurology
- Digital Health

## Offices

- Cambridge, MA, United States
- Osaka, Japan

## People

- Shunichiro Matsumoto — President & CEO
- Daisuke Nakayama — Vice President
- Haruhito Tsutsui — Investment Director
- Kousuke Tani — Senior Investment Director
- Hiroshi Yamamoto — Investment/Operation Senior Advisor
- Ryohei Miyata — Director, Scientific Relations

## Questions

### Who runs investment decisions at Ono Venture Investment?

Shunichiro Matsumoto, PhD, is the President and CEO and leads investment decisions from the South San Francisco office. He joined Ono in 2020 after serving as the president of Astellas Venture Management, where he was a board member for portfolio companies Mitobridge and Potenza Therapeutics. The investment team includes directors with PhD-level training in pharmaceutical sciences and medicinal chemistry, allowing scientific diligence to be conducted in-house.

### How does Ono Venture Investment source its deals?

OVI sources deals through its bi-coastal US presence in South San Francisco and Cambridge, placing PhD-trained investors directly in two of the world's densest biotechnology ecosystems. Team members draw on existing relationships from Ono Pharma's alliance-management and research-collaboration groups, and the firm actively pursues investments in startups whose science can produce novel drug targets or platforms synergistic with Ono's R&D pipeline. The parent company's reputation in immuno-oncology, particularly around Opdivo, provides additional inbound access to emerging biotechs.

### Is Ono Venture Investment structured as a standalone fund or a corporate venture capital unit?

OVI is a single-LP corporate venture capital unit fully funded by Ono Pharma, operating as a division of the publicly traded pharmaceutical company rather than a traditional independent fund. This structure means OVI does not fundraise from external limited partners and is not measured against venture-style return benchmarks. Investment decisions are made on strategic-science fit with Ono's pipeline, and the firm can hold positions for extended development timelines.

### Which therapeutic areas does Ono Venture Investment prioritize?

OVI explicitly prioritizes three therapeutic areas that mirror Ono Pharma's internal R&D focus: oncology, immunology and inflammation, and neurology. The firm seeks to invest in startups possessing platforms or product candidates with high potential synergy to Ono's own drug-development programs. This focus excludes investment in therapeutic categories outside Ono's R&D domain, though Ono maintains a separate CVC, Ono Digital Health Investment, for healthcare-adjacent digital ventures.

### How is Ono Venture Investment related to Ono Digital Health Investment?

Both are corporate venture capital arms of Ono Pharma, but they operate with distinct mandates. OVI focuses on early-stage biotech platform and therapeutics companies in oncology, immunology, inflammation, and neurology — areas directly aligned with Ono Pharma's R&D organization. Ono Digital Health Investment operates with a separate charter, targeting healthcare-related startups more broadly, including digital health and wellness companies that fall outside Ono's traditional pharmaceutical R&D domain.

## Related profiles

- [Onitus Capital](https://altss.com/profile/onitus-capital)
- [OnPlane Financial Advisors](https://altss.com/profile/onplane-financial-advisors)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ono-venture-investment

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology